Current Status of Zika Virus Vaccines: Successes and Challenges
The recently emerged Zika virus (ZIKV) spread to the Americas, causing a spectrum of congenital diseases including microcephaly in newborn and Guillain-Barré syndrome (GBS) in adults. The unprecedented nature of the epidemic and serious diseases associated with the viral infections prompted the glob...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/8/2/266 |
| _version_ | 1797566534066896896 |
|---|---|
| author | Aryamav Pattnaik Bikash R. Sahoo Asit K. Pattnaik |
| author_facet | Aryamav Pattnaik Bikash R. Sahoo Asit K. Pattnaik |
| author_sort | Aryamav Pattnaik |
| collection | DOAJ |
| description | The recently emerged Zika virus (ZIKV) spread to the Americas, causing a spectrum of congenital diseases including microcephaly in newborn and Guillain-Barré syndrome (GBS) in adults. The unprecedented nature of the epidemic and serious diseases associated with the viral infections prompted the global research community to understand the immunopathogenic mechanisms of the virus and rapidly develop safe and efficacious vaccines. This has led to a number of ZIKV vaccine candidates that have shown significant promise in human clinical trials. These candidates include nucleic acid vaccines, inactivated vaccines, viral-vectored vaccines, and attenuated vaccines. Additionally, a number of vaccine candidates have been shown to protect animals in preclinical studies. However, as the epidemic has waned in the last three years, further development of the most promising vaccine candidates faces challenges in clinical efficacy trials, which is needed before a vaccine is brought to licensure. It is important that a coalition of government funding agencies and private sector companies is established to move forward with a safe and effective vaccine ready for deployment when the next ZIKV epidemic occurs. |
| first_indexed | 2024-03-10T19:29:10Z |
| format | Article |
| id | doaj.art-e2f59e38d039456ebc89abddae8c4ba7 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T19:29:10Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-e2f59e38d039456ebc89abddae8c4ba72023-11-20T02:21:12ZengMDPI AGVaccines2076-393X2020-05-018226610.3390/vaccines8020266Current Status of Zika Virus Vaccines: Successes and ChallengesAryamav Pattnaik0Bikash R. Sahoo1Asit K. Pattnaik2School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USASchool of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USASchool of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USAThe recently emerged Zika virus (ZIKV) spread to the Americas, causing a spectrum of congenital diseases including microcephaly in newborn and Guillain-Barré syndrome (GBS) in adults. The unprecedented nature of the epidemic and serious diseases associated with the viral infections prompted the global research community to understand the immunopathogenic mechanisms of the virus and rapidly develop safe and efficacious vaccines. This has led to a number of ZIKV vaccine candidates that have shown significant promise in human clinical trials. These candidates include nucleic acid vaccines, inactivated vaccines, viral-vectored vaccines, and attenuated vaccines. Additionally, a number of vaccine candidates have been shown to protect animals in preclinical studies. However, as the epidemic has waned in the last three years, further development of the most promising vaccine candidates faces challenges in clinical efficacy trials, which is needed before a vaccine is brought to licensure. It is important that a coalition of government funding agencies and private sector companies is established to move forward with a safe and effective vaccine ready for deployment when the next ZIKV epidemic occurs.https://www.mdpi.com/2076-393X/8/2/266Zika virusvaccine platforms and vaccine candidatescorrelates of protectionimmunoinformaticsADE |
| spellingShingle | Aryamav Pattnaik Bikash R. Sahoo Asit K. Pattnaik Current Status of Zika Virus Vaccines: Successes and Challenges Vaccines Zika virus vaccine platforms and vaccine candidates correlates of protection immunoinformatics ADE |
| title | Current Status of Zika Virus Vaccines: Successes and Challenges |
| title_full | Current Status of Zika Virus Vaccines: Successes and Challenges |
| title_fullStr | Current Status of Zika Virus Vaccines: Successes and Challenges |
| title_full_unstemmed | Current Status of Zika Virus Vaccines: Successes and Challenges |
| title_short | Current Status of Zika Virus Vaccines: Successes and Challenges |
| title_sort | current status of zika virus vaccines successes and challenges |
| topic | Zika virus vaccine platforms and vaccine candidates correlates of protection immunoinformatics ADE |
| url | https://www.mdpi.com/2076-393X/8/2/266 |
| work_keys_str_mv | AT aryamavpattnaik currentstatusofzikavirusvaccinessuccessesandchallenges AT bikashrsahoo currentstatusofzikavirusvaccinessuccessesandchallenges AT asitkpattnaik currentstatusofzikavirusvaccinessuccessesandchallenges |